U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07613827) titled 'Interventional AI-Human Collaboration for Steatotic Liver Disease Screening' on May 23.
Brief Summary: Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040. Timely identification and management of intermediate- and high-risk SLD patients are essential, yet early detection remains challenging because current diagnostic modalities, such as biopsy, ultrasonography, and serum indices, are invasive, insensitive, operator-dependent, or difficult to scale. In contrast, non-contrast CT is widely available in routine care ...